Pathophysiology of neuropathic itch and pain - Chronic itch and pain on polyneuropathy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00015167

Enrollment

225

Registered

2019-01-07

Start date

2019-02-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G60 G61 G62 G63 G64

Interventions

Group 1: Patients with polyneuropathy. The primary aim of this project is to investigate the pathophysiology of pain and pruritus in patients with peripheral neuropathy. We plan to investigate 180 pat

we aim to classify these patients by using questionnaires, clinical examinations, sensory testing (QST), neurophysiology and pruritus induction. We expect to identify phenotypic patterns that distingu

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age =18, polyneuropathy, healthy matched controls

Exclusion criteria

Exclusion criteria: Taking antipruritic drugs, infection in the examination area

Design outcomes

Primary

Measure	Time frame
The target value is the average nerve fiber density, IENFD, measured as fiber per millimeter. The following five groups will be compared regarding the IENFD: 1. pruritus and pain, 2. only pain, 3. only pruritus, 4. no pruritus and no pain, 5. healthy controls. A Kruskal-Wallis test (non-parametric test) will be used as the statistical test. During the examination, a biopsy will be taken to measure the nerve fiber density. Furthermore, the patients will be asked to complete a questionnaire.	—

Measure

Time frame

The target value is the average nerve fiber density, IENFD, measured as fiber per millimeter. The following five groups will be compared regarding the IENFD: 1. pruritus and pain, 2. only pain, 3. only pruritus, 4. no pruritus and no pain, 5. healthy controls. A Kruskal-Wallis test (non-parametric test) will be used as the statistical test. During the examination, a biopsy will be taken to measure the nerve fiber density. Furthermore, the patients will be asked to complete a questionnaire.

—

Secondary

Measure	Time frame
QST: individual QST parameters - in comparison between the individual groups and in comparison to healthy controls as well as dependent on clinical symptoms Electrical stimulation results (Threshold / VAS) iontophoresis Itching / pain intensities after stimulation / iontophoresis Duration of itching / pain sensation Flare reaction in patients with and without itching / itching compared to healthy controls as well as dependent on clinical symptoms (with / without pain etc) CMP / CIM: endogenous inhibition (itching / pain) in patients with and without itching / itching compared to healthy controls as well as depending on clinical symptoms itching / pain	—

Measure

Time frame

QST: individual QST parameters - in comparison between the individual groups and in comparison to healthy controls as well as dependent on clinical symptoms Electrical stimulation results (Threshold / VAS) iontophoresis Itching / pain intensities after stimulation / iontophoresis Duration of itching / pain sensation Flare reaction in patients with and without itching / itching compared to healthy controls as well as dependent on clinical symptoms (with / without pain etc) CMP / CIM: endogenous inhibition (itching / pain) in patients with and without itching / itching compared to healthy controls as well as depending on clinical symptoms itching / pain

—

Countries

Germany

Contacts

Public ContactFrank;Esther Birklein;Pogatzki-Zahn

UNIVERSITÄTSMEDIZINder Johannes Gutenberg-Universität MainzKlinik und Poliklinik für Neurologie;Universitätsklinik Münster, Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie

Frank.Birklein@unimedizin-mainz.de;pogatzki@anit.uni-muenster.de+49-6131-175486;0251-8347261

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026